Psychotherapies for prolonged grief disorder in adults: A systematic review and network meta-analysis

Background

Prolonged grief disorder (PGD), a condition characterized by severe, persistent, and disabling grief, is newly included in ICD-11 and DSM-5-TR. Psychotherapies are among the most recommended treatments for PGD, but which should be considered as first-line treatment needs to be clarified. The purpose of this systematic review and network meta-analysis was to synthesize the available evidence to compare five outcomes of different psychotherapies on PGD in adults and identify the optimal psychotherapy modality to inform clinical decision-making for the treatment of PGD.

Method

A comprehensive search was conducted in 7 databases from inception until March 20th, 2023. In the frequentist framework, pairwise and network meta-analyses using random-effects models were performed for outcomes with 95 % confidence interval (CI).

Results

There were 2962 records found and 55 studies (1,0330 participants) assessing 11 different psychological interventions were included. Compared with the waiting list, behavioral therapy (SMD=-1.05; 95 %CI=-1.71, −0.38), third-wave cognitive behavior therapy (SMD=-1.00; 95 %CI =-1.41, −0.58), family therapy (SMD=-0.87; 95 %CI=-1.59, −0.16), psychodynamic therapy (SMD=-0.88; 95 %CI=-1.67, −0.10) and cognitive therapy (SMD=-0.84; 95 %CI=-1.57, −0.12) were statistically effective in reducing grief symptom. Only cognitive behavior therapy (OR =0.48; 95 %CI = 0.27, 0.85) was more acceptable than waiting list. In terms of secondary outcome, third-wave CBT can statistically significantly reduce depression (SMD= −0.60; 95 %CI =- 0.84, −0.36), PTSD (SMD=-0.99; 95 %CI =- 1.62, −0.36) and anxiety (SMD= −1.44; 95 %CI =-2.63, −0.25) respectively.

Conclusions

Most psychological interventions are effective, but only cognitive behavior therapy has the highest acceptability. Third-wave CBT with higher efficacy rates may be more beneficial for reducing secondary outcomes. To provide more robust evidence, high-quality trials should be conducted in the future.